Use of GTF21 mutations in the prognosis of thymic cancers

US9493842B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Giuseppe Giaccone · Bethesda, US
• Yisong Wang · Columbia, US
• Iacopo Petrini · Pisa, IT

Key dates

• Filing date: Apr 2, 2015
• Grant date: Nov 15, 2016
• Expiry date: Apr 2, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/4703
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Disclosed are methods of determining the prognosis of thymic cancer in a subject comprising detecting a mutation in the general transcription factor IIi (GTF2I) genetic sequence or protein. The presence of a GTF2I mutation indicates that the thymic cancer is indolent.